Skip to main content
. 2022 Nov 26;14(12):2614. doi: 10.3390/pharmaceutics14122614

Scheme 1.

Scheme 1

Schematic of the preparation process for CCM@PL showing high affinity toward tumor cells to be used in targeted therapy for cancer.